Loading…
Context Therapeutics Inc.
How the company evolved, year by year. Revenue and debt come from the annual reports — for most companies, the 10-K filings with the SEC since 2009; dividends from the payments themselves.
The bars are a balance on the closing date; the lines are what happened during the year. Revenue above equity is ordinary, not an anomaly — it means the company turns its capital over more than once a year.
Major managers that reported this stock in their latest 13F.
▼ -94.0% over 5Y.
This stock has less than 5 years of price history — the answer would measure a shorter period than the one asked for.
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
The last 5 closed years. Each multiple uses that year’s closing price and that year’s reported numbers — not today’s. The range is set by the annual reports on record.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Year-end price | $1.47 | $1.05 | $1.13 | $0.65 | $2.66 | |
| P/B | 1.0x | 2.2x | 1.0x | 1.5x | 0.3x | 0.9x |
| EPS | -$0.38 | -$0.46 | -$1.50 | -$0.93 | -$3.69 | |
| ROE | -42.68% | -59.73% | -28.05% | -201.87% | -42.68% | -21.66% |
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| ATYRaTYR PHARMA INC | $0.36 | — | 0.7x | — | -98.68% | $34.96M |
| RADXRadiopharm Theranostics Ltd | $2.41 | — | 0.8x | — | -92.10% | $34.84M |
| BDMDBaird Medical Investment Holdings Ltd | $1.12 | — | 0.7x | — | -77.60% | $35.82M |
| HBIOHarvard Bioscience Inc | $7.92 |
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of solid tumors. The company's product candidate includes CTIM-76, a Claudin 6 (CLDN6) x CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. It has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
Company description provided by Yahoo Finance.
Median, not average: a single year of near-zero profit produces a P/E of 400 and would drag an average on its own. P/E years above 200x are left out, the same cut the fair price uses — so this median matches the “its own history” method below. Price and EPS have no median: they are series that grow.
| — |
| 4.9x |
| — |
| -89.95% |
| $36.05M |
| QNCXQuince Therapeutics, Inc. | $33.75 | — | — | — | -153.84% | $34.33M |
| NSYSNortech Systems Inc | $11.84 | 33.8x | 1.0x | — | 3.00% | $33.79M |